

# Effect of Serotonin on Small Intestinal Contractility in Healthy Volunteers

M. B. HANSEN<sup>1</sup>, F. ARIF<sup>1</sup>, H. GREGERSEN<sup>2</sup>, H. BRUUSGAARD<sup>1</sup>, L. WALLIN<sup>1</sup>

<sup>1</sup>Department of Gastrointestinal Surgery D, Glostrup University Hospital of Copenhagen, Glostrup,  
<sup>2</sup>Center for Visceral Biomechanics and Pain, Aalborg Hospital, Denmark

Received December 8, 2006

Accepted January 16, 2007

On-line available May 16, 2007

## Summary

The physiological significance of serotonin released into the intestinal lumen for the regulation of motility is unknown in humans. The aim of this study was to evaluate the effect of serotonin infused into the lumen of the gastric antrum, duodenum or the jejunum, on antro-duodeno-jejunal contractility in healthy human volunteers. Manometric recordings were obtained and the effects of either a standard meal, continuous intravenous infusion of serotonin (20 nmol/kg/min) or intraluminal bolus infusions of graded doses of serotonin (2.5, 25 or 250 nmol) were compared. In addition, platelet-depleted plasma levels of serotonin, blood pressure, heart rate and electrocardiogram were evaluated. All subjects showed similar results. Intravenous serotonin increased migrating motor complex phase III frequency 3-fold and migrating velocity 2-fold. Intraluminal infusion of serotonin did not change contractile activity. Platelet-depleted-plasma levels of serotonin increased 2-fold following both intravenous and high doses of intraluminal infusions of serotonin. All subjects reported minor short-lived adverse effects following intravenous serotonin stimulation, while only half of the subjects reported minor short-lived adverse effects following intraluminal serotonin stimulations. We conclude that exogenous serotonin in the lumen of the upper part of the small intestine does not seem to change antro-duodeno-jejunal contractility significantly in healthy adult volunteers.

## Key words

Blood levels • Human • Intestines • Motility • 5-Hydroxytryptamine • Migrating motor complex • Physiology • Serotonin

## Corresponding author

Mark Berner Hansen, Consultant, MD, DMSci, Department of Gastrointestinal Surgery K, Bispebjerg University Hospital of Copenhagen, DK-2400 Copenhagen NV, Denmark. Fax: +45-35-312891, E-mail: mbh@dadlnet.dk

## Introduction

Large amounts of serotonin (5-hydroxytryptamine, 5-HT) are contained within the intestines, in particular in the duodenum and rectum (Ahlman and Nilsson 2001). 5-HT is a paracrine neuro-endocrine transmitter released to a wide range of stimuli in health and in various disease states (Gershon 2002).

5-HT is released in both fasting and postprandial conditions from sensory cells of the intestinal mucosal lining by several mechanisms (mechanical, chemical and osmotic) (Kellum and Jaffe 1976, Bertrand 2004). 5-HT is released intramurally and intraluminally (Gershon 2002, Gronstad *et al.* 1986, 1987, Kojima 1999, Tanaka *et al.* 2004). The studies in dogs indicate a role for intraluminal (IL) 5-HT for intestinal contraction (Kellum *et al.* 1986). However, the effect of IL 5-HT on intestinal contraction in humans is unknown.

Once released, 5-HT plays a critical physiological role by preparing the intestines for optimal handling of food and pathogenic substances by activating 5-HT receptors on various types of cells including neurones in the enteric nervous system, epithelial cells and smooth muscle cells, causing local hyperemia, secretion for absorptive and digestive purposes, and motility (Gronstad *et al.* 1986, Hansen 2003, Hansen *et al.* 1998, Hansen and Skadhauge 1997). Furthermore, abnormal levels of 5-HT in the circulating blood plasma and in intestinal tissues preparations have been associated with diarrhoea, dysmotility and inflammation. Hence, 5-HT is also believed to play a significant pathophysiological role in some of the functional gastrointestinal disorders (Gershon 2003).

The intestines are quantitatively the most important sites for 5-HT synthesis. Mucosal enterochromaffin (EC) cells are the dominating storage site for 5-HT and are believed to act as mechanosensory elements, which subsequently activate intrinsic sensory neurones that initiate the peristaltic reflex by releasing 5-HT (Hansen 2003). 5-HT is released into the lumen as well as into the portal circulation *via* exocytose and its release is regulated by a complex pattern of neuronal and endocrine inputs (Racke *et al.* 1996). Once released, 5-HT activates at least 5-HT<sub>3</sub>, 5-HT<sub>4</sub>, and 5-HT<sub>7</sub> receptors located on neuronal and muscular structures in the gut wall, for the control of small intestinal motor activity (Hansen 2003, Tonini 2005).

Small intestinal contractility can be subdivided into fasting and postprandial periods. The postprandial period is initiated by the intake of a caloric meal and by definition terminates by the recurrence of phase III of the migrating motor complex (MMC). The MMC cleanse the small intestine and has as such been termed the “gut housekeeper”. One MMC period (cycle) comprises phases I, II and III of which phase III is the most distinctive and easily recognized. The phase III of MMC is characterized by frequency, migration (propagation) velocity and duration (Hansen 2002). Initiation of these organized complexes involves an intricate interaction of the extrinsic (vagal) and intrinsic primary afferent innervation and the endocrine factors (Hansen 2002, 2003). Increase in circulating blood levels of 5-HT increases phase III frequency and migration velocity in healthy humans (Lordal and Hellstrom 1995, Lordal *et al.* 1998), while the effect of increased levels of IL 5-HT remains to be determined.

The primary aim of the study was to investigate how exogenous IL 5-HT affects small intestinal contractility in healthy humans. We used antro-duodeno-jejunal manometry to assess this.

## Methods

### Subjects

Four healthy volunteers participated in the study (Table 1). Due to the potential risk by infusion of serotonin and since all the studied subjects experienced adverse effects and showed similar patterns of manometric and other responses, we did not include more than 4 subjects. The fertile female subject was examined in the luteal phase of her menstrual cycle. No subjects were taking any kind of medication and none reported

**Table 1.** Characteristics for subjects are presented.

	Subjects			
	AB	LZ	MM	VA
<i>Age (years)</i>	24	23	57	51
<i>Gender</i>	M	F	M	F
<i>BMI</i>	23	26	27	28

Initials of names, age, gender (M = male, F= female) and body mass index (BMI).

symptoms or a history of gastrointestinal or cardiovascular disease. All subjects drank below the recommended safe alcohol limit (<14 and 21 units/week for females and males, respectively) and did not smoke on a daily basis. Intake of acetaminophen, tryptophan-rich foods (e.g. invertebrate, banana, kiwi fruit, chocolate, tomato, and nuts) and cigarette smoking, all of which might influence 5-HT body content, was prohibited 24 h prior to examinations. Subjects had a normal clinical examination, body mass index (less than 30), electrocardiogram, and hemodynamic parameters (blood pressure and heart rate) prior to examinations. None of the subjects had participated in a clinical trial of any drug within the previous month.

### Ethics

The subjects gave written informed consent for participation in this study, which was approved by the Research Ethics Committee of Copenhagen (KA 97170) and The Danish Medicines Agency (2612-1501). Subjects received a minor financial compensation for participation.

### Protocol

Each subject was examined in the morning on three separate days (day 1-3) after fasting overnight. The manometry catheter was placed (see details below) and veins on both arms were cannulated: one for infusion and the other for obtaining blood samples. The recordings started (time = 0 min) with the subjects at rest in the supine position. During all examinations the subjects received intravenous saline 0.9 % (1 ml/min). Subjects were initially examined for a basal resting period of 180 min in the fasting condition. Due to the recognized inter-individual (but not intra-individual) variability in the cyclic pattern of contractile activity of the small intestine (Hansen 2002), the fasting period for each subject served as its own control to the subsequent meal or 5-HT stimulation. All examinations ended after 300 min.

On day 1, meal stimulation was performed at time = 180 min with the intake of a mixed liquid meal (Nutridrink®, 25 °C, 4 ml/kg = 630 kJ/kg, 390 mOsm/l, composed as a % of energy: proteins 13 %, carbohydrates 48 % and fat 39 %, multiple vitamins and minerals, and kindly donated by Nutricia A/S, DK).

On day 2, intravenous (IV) 5-HT stimulation was performed at time = 180 min with continuous infusion for 60 min of 5-HT (5-hydroxytryptamine creatinine sulphate, 20 nmol/kg/min, purchased at Sigma Chemicals, DK, and prepared for infusion at Herlev University Hospital Pharmacy of Copenhagen, DK). The dose of 5-HT was selected based on pilot studies. Higher doses than 20 nmol/kg/min 5-HT was unacceptable due to high incidence of severe adverse effects (e.g. heat of the head, redness, burning, tenderness, strong heart beat, and heat sensation).

On day 3, intraluminal (IL) 5-HT stimulation was performed. Bolus infusions (16 in total, with 15 min intervals) were started at time = 60 min. Bolus infusions consisted of 10 ml saline 0.9 % alone (4 in total) or 10 ml saline 0.9 % containing increasing graded doses of 5-HT (5-hydroxytryptamine creatinine sulphate, 2.5, 5 and 250 nmol, purchased at Sigma Chemicals, DK, and prepared for infusion in our laboratory) (12 in total) (see Tables 2 and 3). The selected dose of 5-HT was based on reports from the literature (Kellum *et al.* 1976, Gronstad *et al.* 1986, 1987, Hansen and Jaffe 1994, Zhu *et al.* 2001, Ferrara *et al.* 1986, Tanaka *et al.* 2004). The bolus infusions were given subsequently, first in channel 7 (J3), which was the channel with the most aborally located sensors/side holes in the jejunum, subsequently in channel 5 (J1), in channel 3 (D1) and finally in channel 1 (A1) located in the antrum of the stomach (Table 2, Fig. 1). Bolus infusions of saline alone were followed by bolus infusions of saline added accumulating graded doses of 5-HT (Fig. 1).

Venous blood samples were obtained for measurement of 5-HT levels. Blood samples were collected at the end of the fasting period in all examinations on day 2 and day 3 (time = 170 min), at the end of the period with IV infusion of 5-HT (time = 240 min) on day 2, and at the end of the periods with IL infusion of 25 nmol 5-HT (time = 240 min) and 250 nmol 5-HT (time = 300 min) on day 3.

Blood pressure, heart rate and electrocardiogram were monitored every 15 min throughout all examinations. Symptoms reported by the subjects during the examinations were recorded. The subject was blinded

to what was infused on day 3 (IL 5-HT stimulation), but it was not possible to blind the subject during examinations on day 1 (meal stimulation) or day 2 (IV 5-HT stimulation).

#### *Manometric recordings*


The contractility pattern was monitored by manometry. A 250 cm long and 7-channel (lumen/sensor) polyvinyl catheter was introduced *via* the nose and fluoroscopy was used to position the catheter in such a way that two channels with side holes were located in the antrum of the stomach (A1 and A2), two in the duodenum (D1 and D2) and the three remaining in the jejunum (J1, J2 and J3) (Table 2). Each channel was connected to an external pressure transducer and a low-compliance pneumohydraulic water-perfused system. Pressure transducers were coupled to an AD-converter and a computer for data sampling and analysis (GMC Aps, Denmark). The channels and side-holes served as the route for IL bolus infusions of saline and 5-HT.

#### *Analysis of manometry recordings*

Two blinded observers, who worked together and agreed upon the presence or the absence of specific motor patterns, evaluated the manometric recordings. They analyzed visually the start and the end of phase III of the MMC. Phase III was identified according to the criteria of Vantrappen *et al.* (1977): a) appearance of uninterrupted bursts of rhythmic pressure waves with a frequency of 11-12 contractions per min and lasting for at least 2 min in each segment, b) aboral migration of activity passing at least the distal two registration points (three recording sites in total), and c) a period of complete quiescence after phase III activity. Antral phase III had to be followed by duodenal phase III and the site of origin of each phase III was noted. Total MMC cycle length was calculated from the end of phase III to the end of the next phase III. Pressure wave frequency and amplitude were calculated for 10-min periods, from 10 min before infusion until 30 min after the start of infusion. Phase III propagation in each segment (duodenum and jejunum) was calculated from the start of phase III. The time-interval between the start of saline/5-HT infusion to the appearance of phase III was calculated for each segment separately. The second antral (A2), second duodenal (D2) and third jejunal channel (J3) was used to describe the MMC and pressure wave characteristics.

**Table 2.** Design of the manometric catheter (total length of 250 cm). The tip of the catheter was located in jejunum. 7 channels with side holes recorded pressure changes: channel 1 and 2 (A1 and A2) were placed 5 cm apart in the antrum of the stomach. Channel 3 and 4 (D1 and D2) were placed 10 cm apart in duodenum and the distance between channel 2 and 3 was 10 cm. Channel 5, 6 and 7 (J1, J2 and J3) were placed 10 cm apart the jejunum and the distance between channel 4 and 5 was 20 cm. The final part of catheter to the tip was 5 cm long.

Channel	A1	A2	D1	D2	J1	J2	J3	End
Start	Stomach	Stomach	Duodenum	Duodenum	Jejunum	Jejunum	Jejunum	End
0 cm	180 cm	185 cm	195 cm	205 cm	225 cm	235 cm	245 cm	250 cm



**Fig. 1.** Study design for examination with intraluminal (IL) stimulation. After an equilibrium period of 60 min, IL bolus infusions of saline alone or saline added graded doses of 5-HT (2.5, 25 or 250 nmol) were injected directly through the recording channels (side holes) of the catheter into the stomach (A1 and A2), duodenum (D1 and D2), and jejunum (J1, J2, and J3) with 15 min intervals. Injections started aborally in order to reduce "down-stream-flow" bias effects. Examination ended at time = 300 min.

**Table 3.** Phase III of the migrating motor complex (MMC) is a band of regular pressure waves at the slow wave frequency that migrates down through the proximal small bowel to terminate between the midpoint of the small bowel and the terminal ileum. It recurs and is characterized by various parameters such as occurrence frequency, migration velocity, and duration (Hansen 2002). Data presents phase III characteristics for the duodeno-jejunal (sensor D2-J1) segment: fasting (for 3 h, pre-stimulatory) and post-stimulatory after either intravenous (IV) continuous infusion of 5-HT (20 nmol/kg/min for 1 h) or intraluminal (IL) bolus infusions of 5-HT (250 nmol for 1 h).

Characteristics of phase III	Fasting	IV 5-HT	IL 5-HT
Frequency (number/hr)	0.2 (0-1)	3.3 (2-5)*	0.2 (0-1)
Migration velocity (cm/min)	10.2 ± 9.1	20.3 ± 7.4**	7.4 ± 2.3
Duration (min)	8.3 ± 2.2	7.1 ± 4.4	8.3 ± 4.1

Data are presented for all 4 subjects as medians (range) for occurrence frequency and as mean values ± SD for migration velocity and duration. \* p = 0.036, \*\* p = 0.041.

#### Analysis of 5-HT levels

Venous blood samples (2.5 ml) were collected into a cold (2-8 °C) polystyrene tube containing sodium EDTA (5 mmol/l), mixed gently by inversion and immediately cooled on ice. Within 10 min, samples were centrifuged at 4000 rpm/1700 g for 30 min at 40 °C. The upper two-thirds of the platelet-depleted plasma (PDP) was transferred to polystyrene tubes and stored at -200 °C. 5-HT levels in PDP samples were measured using enzyme immunoassay (Immunotech, Marseille, France).

#### Data and statistical analysis

Data are expressed as means ± SD or medians (range). Effects of 5-HT on phase III characteristics, PDP levels of 5-HT, and hemodynamics were examined. Statistical analysis was done with the SigmaStat 3.2. package (SPSS Incl., Chicago, IL, USA). The statistical significance was evaluated using Wilcoxon's test for paired data of two groups, Mann-Whitney test for unpaired data of two groups, and analysis of variance (ANOVA) for comparison of more than two groups. Differences resulting in p<0.05 values were regarded as statistically significant.

## Results

### *Manometric recordings during fasting conditions and under meal stimulation*

All subjects demonstrated normal fasting patterns in all examinations (Table 3). Phase III characteristics varied somewhat between subjects and almost all phase IIIs originated in the duodenum and migrated all to the jejunum. All subject demonstrated normal postprandial patterns (data not shown) and the MMC returned within 180 min.

#### *5-HT stimulation*

All subjects responded with an increase in phase III occurrence frequency and migration velocity within 10 min following stimulation with IV 5-HT (Table 3). IV 5-HT did not change, however, the duration of phase III's. IL infusion of 5-HT did not change any of the phase III characteristics (Table 3). Specifically, the frequency (and the interval time between phase IIIs), migration velocity and duration of phase III's did not change. There was no change in the contraction pattern of phase I and phase II and the amplitude of contractions in phase I, phase II and phase III was within normal values and did not change during examinations (data not shown).

### *Platelet-depleted-plasma levels of 5-HT*

#### *Intravenous 5-HT stimulation*

The PDP levels of 5-HT in the fasting period (time = 170 min) varied considerably between subjects but increased significantly from  $40 \pm 22$  to  $81 \pm 35$  nmol/l ( $p=0.032$ ) following IV infusion of 5-HT (time = 240 min).

#### *Intraluminal 5-HT stimulation*

The PDP levels of 5-HT in the fasting period (time = 60 min) varied considerably between subjects ( $72 \pm 76$  nmol/l). The PDP levels were unchanged ( $61 \pm 56$  nmol/l) at the end of the stimulation period with bolus infusions of saline alone (time = 120 min). Nor did the PDP levels change at the end of periods with infusions of 25 nmol 5-HT ( $32 \pm 18$  nmol/l, time = 240 min). However, PDP-levels of 5-HT increased significantly to  $67 \pm 18$  nmol/l ( $p=0.035$ ) following periods with infusion of 250 nmol 5-HT (time = 300 min).

### *Hemodynamic parameters*

#### *Meal stimulation*

The hemodynamic parameters were within

normal values in the fasting period (systolic blood pressure,  $126 \pm 6$  mm Hg, diastolic blood pressure,  $76 \pm 8$  mm Hg, heart rate,  $62 \pm 14$  beats/min). No significant changes in blood pressure, heart rate or electrocardiography were observed following meal stimulation (data not shown).

#### *Intravenous 5-HT stimulation*

The hemodynamic parameters were within normal values in the fasting period. During stimulation with IV 5-HT, there was no significant change in blood pressure, heart rate (Table 4) or electrocardiography (data not shown).

#### *Intraluminal 5-HT stimulation*

The hemodynamic parameters were within normal values in the fasting condition. During stimulation with IL 5-HT, there was no significant change in blood pressure, heart rate (Table 5) or electrocardiography (data not shown).

### *Adverse effects*

#### *Meal stimulation*

No adverse effects were reported during fasting or following meal stimulation.

#### *Intravenous 5-HT stimulation*

During periods with IV infusion of 5-HT, all the subjects reported one or more of the following symptoms: tenderness (3 subjects), heat sensation (3 subjects), redness (1 subject), and burning sensation (1 subject) in the infused arm, sensation of strong heartbeat (1 subject) and heat of the head (1 subject). All symptoms disappeared completely within 10 min after ending 5-HT infusion. None of the subjects wanted to stop the examination and none of subjects has reported late adverse effects.

#### *Intraluminal 5-HT stimulation*

During periods with IL infusion of 250 nmol 5-HT, 2 of the 4 subjects reported one or more of the following symptoms: tenderness (2 subjects), heat sensation (2 subjects), sensation of strong heartbeat (1 subject) and heat of the head (1 subject). Adverse effects were not observed following infusion of 2.5 nmol and 25 nmol doses of 5-HT. All symptoms disappeared completely within 10 min after ending 5-HT infusion. None of the subjects asked to stop the examination and none of subjects has reported late adverse effects.

**Table 4.** Data presents hemodynamics characteristics at the end of examinations periods with IV infusion with saline alone or saline added 5-HT (20 nmol/kg/min).

Hemodynamics following IV 5-HT	Saline	Saline + 5-HT
<i>Systolic blood pressure (mm Hg)</i>	116 ± 6	119 ± 20 (p=0.80)
<i>Diastolic blood pressure (mm Hg)</i>	68 ± 9	79 ± 16 (p=0.45)
<i>Heart rate (beats per minute)</i>	57 ± 9	64 ± 18 (p=0.66)

Data are presented as mean values ± SD in 4 subjects. P is compared to saline alone.

**Table 5.** Data presents hemodynamics characteristics at the end of the examinations periods with IL bolus infusion with saline alone or saline added 5-HT in accumulating graded doses (2.5, 25 and 250 nmol).

Hemodynamics following IL 5-HT	Saline	Saline + 5-HT 2.5 nmol	Saline + 5-HT 25 nmol	Saline + 5-HT 250 nmol
<i>Systolic blood pressure (mm Hg)</i>	128 ± 5	129 ± 12	125 ± 10	130 ± 25 (p=0.70)
<i>Diastolic blood pressure (mm Hg)</i>	75 ± 10	74 ± 19	75 ± 19	91 ± 21 (p=0.33)
<i>Heart rate (beats per minute)</i>	60 ± 13	61 ± 10	61 ± 14	63 ± 19 (p=0.44)

Data are presented as mean values ± SD in 4 subjects. P is compared to saline alone

## Discussion

A distinctive feature of physiological regulation of the intestines is that stimuli of hormonal release and neural activation arise within the lumen from the mechanical and chemical properties of food and digestive secretions. One of these neuroendocrine substances is 5-HT which has a pivotal role in modulating intestinal functions including secretion, blood flow and peristaltic motor activity (Hansen 2003, Hansen *et al.* 1998, Hansen and Skadhauge 1997, Ormsbee *et al.* 1984). Furthermore, changes in 5-HT metabolism have been demonstrated in some disorders of intestinal function. Consequently, there is a rationale for using serotonergic agents for treatment of functional gastrointestinal disorders such as irritable bowel syndrome (Baker 2005, Kilkens *et al.* 2004).

When exogenous 5-HT is applied into the intestinal lumen in doses comparable to those released by physiological stimuli (0.016 mg/ml, about 40 nmol/ml), a localized vasodilatation occurs in the intestinal mucosal and submucosal layers (Gronstad *et al.* 1986, Hansen *et al.* 1998). Exogenous 5-HT also stimulates intestinal secretions. However, it acts with less potency when exposed to luminal side as compared to the serosal side of the epithelia (Hansen and Skadhauge 1997). Hence, we hypothesized that both IV and IL stimulation with 5-HT would have similar effects on intestinal contractility but with different potencies.

The present study suggests that selective local increase in IL levels of 5-HT, in contrary to circulating (i.e. IV) plasma levels, does not alter small intestinal contractility significantly in healthy volunteers. The results from our study are therefore discussed in relation to findings reported in the literature, keeping in mind the small number of subjects studied and the associated potential risk of misinterpretations due to type II statistical error.

### Manometric recordings

In this study we used manometry to assess small intestinal contractility. Manometry provides detailed information on the functional neuromuscular integrity so that myopathy and neuropathy can be diagnosed accordingly (Hansen 2002). However, manometry does not allow us to identify the underlying specific disease in case of neuromuscular dysfunction. Accordingly small intestinal motility can be impaired as a consequence of disease processes (e.g. some inflammatory, connective tissue and vascular diseases) that primarily do not affect neuromuscular function (Husebye 1999).

All subjects in this study demonstrated normal fasting and postprandial patterns of contractility with the expected biological variations in phase III characteristics (Hansen 2003). Hence, all subjects were considered to be healthy with respect to the intestinal neuromuscular function and continued to examinations with 5-HT stimulation.

### *Serotonin and the migrating motor complex*

Ormsbee *et al.* (1984) presented the evidence for a role of endogenous 5-HT in the regulation of the MMC. Depleting the endogenous 5-HT stores in dogs reduced the phase III activity. Other animal studies have supported these findings: the MMC cycling frequency is increased following inhibition of 5-HT reuptake mechanisms (Gorard *et al.* 1994) and following supplementing the diet with the 5-HT precursor 5-hydroxytryptophan, whereas selective destruction of 5-HT neurons in the myenteric plexus results in a decrease in MMC cycling frequency (Sagrada *et al.* 1990). Furthermore, the concentrations of circulating and luminal 5-HT have been demonstrated to cycle in close temporal association with the MMC in dogs (Haga *et al.* 1996, Tanaka *et al.* 2004) with peak concentrations at the end of phase II (Tanaka *et al.* 2004).

All subjects responded to stimulation with IV 5-HT with an increase in phase III frequency and migration velocity. This is consistent with previous studies in dogs (Ormsbee *et al.* 1984) and humans (Lordal *et al.* 1998). IL infusions of 5-HT did not change any of the phase III characteristics. These results are consistent with studies in dogs, where the release of 5-HT in Thiery-Vella loops or intraduodenal infusion of low doses of 5-HT (20-400 ng/min, about 0.05-1 nmol/min) did not change the MMC characteristics (Ferrara *et al.* 1986, Tanaka *et al.* 2004).

We do not know why stimulation with the highest dose of IL 5-HT did not induce similar manometric changes as IV 5-HT despite PDP 5-HT levels increased to similar levels as those following IV 5-HT. As intrinsic primary neuronal activity is only altered by mucosal and luminal stimulators (mechanical, chemical, etc.), but not by circulating substances, we speculate that IL 5-HT induces compensatory mechanisms by which the contracting effects of circulating 5-HT are counteracted (Hansen 2003).

### *Platelet-depleted-plasma levels of 5-HT*

Only 5-HT concentrations measured as PDP levels more accurately reflect acute changes, whereas those in platelet-rich-plasma and platelets alone are more indicative of any change over time (Houghton *et al.* 2003).

As expected the PDP levels of 5-HT varied significantly between subjects during both fasting and post-stimulatory conditions. PDP levels of 5-HT double following meal stimulation (Hansen *et al.* 2006),

following stimulation with IV 5-HT and high doses of IL 5-HT but not following stimulation with low doses of IL 5-HT (this study). Inactivation of 5-HT is accomplished by reuptake of the amine by mucosal EC cells, mast cells, epithelial cells, neurons and platelets, and by enzymatic degradation by monoamine oxidase in the liver and lungs. This is followed by urinary excretion of its main metabolite, 5-hydroxyindole-3-acetic acid (Wade *et al.* 1996). We speculate that the differences in PDP levels of 5-HT following stimulation with low doses of IL 5-HT as compared to the high dose of IL 5-HT and IV 5-HT were due to saturation of the elimination capacity.

### *Hemodynamic parameters*

In healthy humans intravenous infusion of 60 nmol/min/kg, but not 15 nmol/min/kg, of 5-HT over 30 min has been reported to cause positive inotropic but no chronotropic cardiac effect (Lordal *et al.* 1998). In animals sustained high blood levels of 5-HT cause positive inotropic, chronotropic and proarrhythmic effects (Kaumann *et al.* 1991, Zinner *et al.* 1983). In particular prolongation of the QT-segment is potentially lethal and the reason why some 5-HT<sub>4</sub> receptor agonists never will be used in clinics. Despite significant increases in PDP levels of 5-HT in our study neither IV, nor IL 5-HT stimulation changed the hemodynamic parameters significantly. Stimulations with 5-HT were also devoid of arrhythmic side effects. Thus our results are consistent with previous reports and together they suggest that IV doses of 5-HT higher than 20 nmol/kg/min are needed in order to cause significant inotropic effects and even higher doses are needed to cause chronotropic and proarrhythmic effects in healthy humans.

### *Adverse effects*

The incidence of adverse effects seemed to correspond well with PDP levels. However, the profile of adverse effects was different from another similar study, where subjects received up to 60 nmol/min/kg of IV 5-HT in a stepwise design (Lordal *et al.* 1998). To our surprise, none of the subjects in our study complained about nausea, vomiting, mental discomfort or abdominal cramps, which could result from increased intestinal contractility and phase III activity. Another unanswered question is why not all of the subject's experienced adverse effects following IL infusion of the highest dose of 5-HT, although PDP levels increased to similar levels as following IV infusion of 5-HT. We speculate that increasing the infused doses of 5-HT in a stepwise

manner alters receptor sensitivity to 5-HT on neuronal structures in the peripheral and central nervous system and thereby changes the experience of adverse effects.

## Conclusions

The present study suggests that exogenous intraluminal 5-HT, in contrast to exogenous intravenous 5-HT, does not affect contractility of the small intestine in healthy humans.

## Conflict of Interest

There is no conflict of interest.

## Acknowledgements

Part of the data has been presented at meetings and

published in connection with these as abstracts in *Neurogastroenterol & Motility* 15 (5), 581, 2003 and in *Acta Physiol Scand* 181 (1), 1-163, 2004.

This work was kindly supported by Sofus Carl Emil Friis and his wife Olga Friis Foundation, The Carlsberg Foundation, The Enid Ingemann Foundation, Else and Mogens Wedell-Wedellsborg Foundation, Dagmar Marshall Foundation, The Lundbeck Foundation, The Novo Nordisk Foundation, C.C. Klestrup and his wife Henriette Klestrup Foundation, The Danish Medical Association Research Foundation, The Danish Hospital Foundation for Medical Research in Region of Copenhagen, The Faeroe Islands and Greenland, and The Gangsted Foundation. We thank Lene Appelt and Trine Schnoor for their assistance with experiments.

## References

- AHLMAN H, NILSSON I: The gut as the largest endocrine organ in the body. *Ann Oncol* **12** (Suppl 2): S62-S68, 2001.
- BAKER DE: Rationale for using serotonergic agents to treat irritable bowel syndrome. *Am J Health Syst Pharm* **62**: 700-711, 2005.
- BERTRAND PP: Real-time detection of serotonin release from enterochromaffin cells of the guinea pig ileum. *Neurogastroenterol Motil* **16**: 511-514, 2004.
- FERRARA A, ZINNER MJ, HINSDALE JG, JAFFE BM: Intraluminal release of serotonin during the interdigestive migrating complex in the canine small intestine. *J Surg Res* **41**: 308-311, 1986.
- GERSHON MD: Importance of serotonergic mechanisms in gastrointestinal motility and sensation. In: *Irritable Bowel Syndrome*. CAMILLERI M, SPILLER RC (eds), WB Saunders, Edinburgh, 2002, pp 95-116.
- GERSHON MD: Serotonin and its implication for the management of irritable bowel syndrome. *Rev Gastroenterol Disord* **3** (Suppl 2): S25-S34, 2003.
- GORARD DA, LIBBY GW, FARTHING MJ: 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. *Gut* **35**: 496-500, 1994.
- GRONSTAD KO, DAHLSTROM A, JAFFE BM, AHLMAN H: Regional and selective changes in blood flow of the feline small intestine induced by endoluminal serotonin. *Acta Physiol Scand* **127**: 207-213, 1986.
- GRONSTAD K, DAHLSTROM A, FLORENCE L, ZINNER MJ, AHLMAN J, JAFFE BM: Regulatory mechanisms in endoluminal release of serotonin and substance P from feline jejunum. *Dig Dis Sci* **32**: 393-400, 1987.
- HAGA N, MIZUMOTO A, SATOH M, MOCHIKI E, MIZUSAWA F, OHSHIMA K, ITOH Z: Role of endogenous 5-hydroxytryptamine in the regulation of gastric contractions by motilin in dogs. *Am J Physiol* **270**: G20-G28, 1996.
- HANSEN MB: Small intestinal manometry. *Physiol Res* **51**: 541-556, 2002.
- HANSEN MB: Neurohumoral control of gastrointestinal motility. *Physiol Res* **52**: 1-30, 2003.
- HANSEN MB, JAFFE BM: 5-HT receptor subtypes involved in luminal serotonin-induced secretion in rat intestine in vivo. *J Surg Res* **56**: 277-287, 1994.
- HANSEN MB, SKADHAUGE E: Signal transduction pathways for serotonin as an intestinal secretagogue. *Comp Biochem Physiol A* **118**: 283-290, 1997.
- HANSEN MB, DRESNER LS, WAIT RB: Profile of neurohumoral agents on mesenteric and intestinal blood flow in health and disease. *Physiol Res* **47**: 307-327, 1998.
- HANSEN MB, ARIF F, WALLIN, PEDERSEN JF: Serotonin and superior mesenteric artery resistance index. *Scand J Clin Lab Invest* **66**: 395-406, 2006.

- HOUGHTON LA, ATKINSON W, WHITAKER RP, WHORWELL PJ, RIMMER MJ: Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. *Gut* **52**: 663-670, 2003.
- HUSEBYE E: The patterns of small bowel motility: physiology and implications in organic disease and functional disorders. *Neurogastroenterol Motil* **11**: 141-161, 1999.
- KAUMANN AJ, SANDERS L, BROWN, AM, MURRRAY KJ, BROWN MJ: A 5-HT<sub>4</sub>-like receptor in human right atrium. *Naunyn Schmiedebergs Arch Pharmacol* **344**: 150-159, 1991.
- KELLUM JM, Jr., JAFFE BM: Release of immunoreactive serotonin following acid perfusion of the duodenum. *Ann Surg* **184**: 633-636, 1976.
- KELLUM JM, MAXWELL JD, POTTER J, KUMMERLE JF: Motilin's induction of phasic contractility in canine jejunum is mediated by the luminal release of serotonin. *Surgery* **100**: 445-453, 1986.
- KILKENS TO, HONIG A, VAN NIEUWENHOVEN MA, RIEDEL WJ, BRUMMER RJ: Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls. *Gut* **53**: 1794-1800, 2004.
- KOJIMA S: KW-5092, a novel gastrokinetic agent, facilitates luminal serotonin release from the guinea-pig colon. *Eur J Pharmacol* **374**: 113-115, 1999.
- LORDAL M, HELLSTROM PM: 5-Hydroxytryptamine: initiator of phase 3 of migrating motor complex. *Acta Physiol Scand* **155**: 241-242, 1995.
- LORDAL M, WALLEN H, HJEMDAHL P, BECK O, HELLSTROM PM: Concentration-dependent stimulation of intestinal phase III of migrating motor complex by circulating serotonin in humans. *Clin Sci* **94**: 663-670, 1998.
- ORMSBEE HS, SILBER DA, HARDY FE Jr: Serotonin regulation of the canine migrating motor complex. *J Pharmacol Exp Ther* **231**: 436-440, 1984.
- RACKE K, REIMANN A, SCHWORER H, KILBINGER H: Regulation of 5-HT release from enterochromaffin cells. *Behav Brain Res*, **73**: 83-87, 1996.
- SAGRADA A, BRANCACCIO N, SCHIAVONE A: 5-Hydroxytryptamine affects rat migrating myoelectric complexes through different receptor subtypes: evidence from 5-hydroxytryptophan administration. *Life Sci* **46**: 1207-1216, 1990.
- TANAKA T, MIZUMOTO A, MOCHIKI E, HAGA N, SUZUKI H, ITOH Z: Relationship between intraduodenal 5-hydroxytryptamine release and interdigestive contractions in dogs. *J Smooth Muscle Res* **40**: 75-84, 2004.
- TONINI M: 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors. *NeurogastroenterolMotil* **17**: 637-642, 2005.
- VANTRAPPEN G, JANSSENS J, HELLEMANS J, GHOOS Y: The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. *J Clin Invest* **59**: 1158-1166, 1977.
- WADE PR, CHEN J, JAFFE B, KASSEM IS, BLAKELY RD, GERSHON MD: Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. *J Neurosci* **16**: 2352-2364, 1996.
- ZINNER MJ, KASHER F, JAFFE BM: The hemodynamic effects of intravenous infusions of serotonin in conscious dogs. *J Surg Res*, **34**: 171-178, 1983.
- ZHU JX, ZHU XY, OWYANG C, LI Y: Intestinal serotonin acts as a paracrine substance to mediate vagal signal transmission evoked by luminal factors in the rat. *J Physiol Lond* **530**: 431-442, 2001.
-